Abstract
Ketamine is a noncompetitive antagonist of the NMDA-receptors, used as a dissociative anesthetic, presently included in the category of the psychoactive substances known as “club drugs”. Ketamine administration was associated with impaired working memory and increased psychopathological symptoms, but there is a lack of information regarding the effects of chronic sub-anesthetic doses. Adult Wistar rats were administered ketamine, 5 and 10 mg/kg twice daily, subcutaneously for 14 days. One week later, rats were tested in an object recognition/object location task and in the open field arena. There was altered performance in both the object recognition/location and in the open field tests by the group chronically exposed to the lower dose of ketamine. These animals displayed a decreased discrimination index (p < 0.05) in the object recognition task, were unable to recognize the displacement of a familiar object and displayed decreased activity across open filed sessions. Importantly, these alterations were not observed in animals administered a higher dose of ketamine. Collectively, these results consistently show that chronic administration of ketamine in sub-anesthetic doses may lead to decreased habituation and inability to update spatial representations.
Keywords: Ketamine, spatial recognition; memory, habituation, long-term effects
Current Neuropharmacology
Title: Impaired Spatial Memory after Ketamine Administration in Chronic Low Doses
Volume: 9 Issue: 1
Author(s): C. Venancio, A. Magalhaes, L. Antunes and T. Summavielle
Affiliation:
Keywords: Ketamine, spatial recognition; memory, habituation, long-term effects
Abstract: Ketamine is a noncompetitive antagonist of the NMDA-receptors, used as a dissociative anesthetic, presently included in the category of the psychoactive substances known as “club drugs”. Ketamine administration was associated with impaired working memory and increased psychopathological symptoms, but there is a lack of information regarding the effects of chronic sub-anesthetic doses. Adult Wistar rats were administered ketamine, 5 and 10 mg/kg twice daily, subcutaneously for 14 days. One week later, rats were tested in an object recognition/object location task and in the open field arena. There was altered performance in both the object recognition/location and in the open field tests by the group chronically exposed to the lower dose of ketamine. These animals displayed a decreased discrimination index (p < 0.05) in the object recognition task, were unable to recognize the displacement of a familiar object and displayed decreased activity across open filed sessions. Importantly, these alterations were not observed in animals administered a higher dose of ketamine. Collectively, these results consistently show that chronic administration of ketamine in sub-anesthetic doses may lead to decreased habituation and inability to update spatial representations.
Export Options
About this article
Cite this article as:
Venancio C., Magalhaes A., Antunes L. and Summavielle T., Impaired Spatial Memory after Ketamine Administration in Chronic Low Doses, Current Neuropharmacology 2011; 9 (1) . https://dx.doi.org/10.2174/157015911795016912
DOI https://dx.doi.org/10.2174/157015911795016912 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Identification of Crucial Genes and Diagnostic Value Analysis in Major Depressive Disorder Using Bioinformatics Analysis
Combinatorial Chemistry & High Throughput Screening Use of Medications for the Treatment of Alcohol Dependence: A Retrospective Study Conducted in 2011-2012
Current Drug Research Reviews Alzheimer’s Disease Risk and Progression: The Role of Nutritional Supplements and their Effect on Drug Therapy Outcome
Current Neuropharmacology Parkinson’s Disease: Alpha Synuclein, Heme Oxygenase and Biotherapeutic Countermeasures
Current Pharmaceutical Design Cocaine and Acute Vascular Diseases
Current Drug Abuse Reviews Theory of Mind in the Early Course of Schizophrenia
Current Psychiatry Reviews Anomalies of Self in First-Episode Psychosis
Current Psychiatry Reviews New Developments in Understanding and Treating Adolescent Marijuana Dependence
Adolescent Psychiatry Novel Approach to the Role of NMDA Receptors in Traumatic Brain Injury
CNS & Neurological Disorders - Drug Targets A Feature-Free 30-Disease Pathological Brain Detection System by Linear Regression Classifier
CNS & Neurological Disorders - Drug Targets Neuroprotective Strategies for Parkinsons Disease
Current Neuropharmacology Analysis of Anti-Inflammatory Enantiomers by HPLC in Human Plasma and Urine: A Review
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Using Functional Neuroimaging to Investigate the Mechanisms of Action of Selective Serotonin Reuptake Inhibitors (SSRIs)
Current Pharmaceutical Design Sudden Infant Death Syndrome from Epidemiology to Pathophysiology
Current Pediatric Reviews Impact of Cytokines and Chemokines on Alzheimer’s Disease Neuropathological Hallmarks
Current Alzheimer Research Diabetes Mellitus, Hypertension and Hypercholesterolemia in Relation to the 10-Year ACS Prognosis; the GREECS Study
Current Vascular Pharmacology TCR Peptide Vaccination in Multiple Sclerosis: Boosting a Deficient Natural Regulatory Network that may Involve TCR-Specific CD4+CD25+ Treg Cells
Current Drug Targets - Inflammation & Allergy Specific Therapy Based on the Genotype and Cellular Mechanism in Inherited Cardiac Arrhythmias. Long QT Syndrome and Brugada Syndrome
Current Pharmaceutical Design The Emerging Role of Sunitinib in the Treatment of Advanced Epithelial Thyroid Cancer: Our Experience and Review of Literature
Mini-Reviews in Medicinal Chemistry Possible Drug Candidates for Alzheimers Disease Deduced from Studying their Binding Interactions with α7 Nicotinic Acetylcholine Receptor
Medicinal Chemistry